| Literature DB >> 31753206 |
Julien Ternacle1, Laura Krapf2, Dania Mohty3, Julien Magne4, Annabelle Nguyen5, Arnault Galat5, Romain Gallet5, Emmanuel Teiger5, Nancy Côté6, Marie-Annick Clavel6, François Tournoux7, Philippe Pibarot8, Thibaud Damy5.
Abstract
The prevalence of calcific aortic stenosis (AS) and of cardiac amyloidosis (CA) increases with age, and their association is not uncommon in the elderly. The identification of CA is particularly challenging in patients with AS because these 2 conditions share several features. It is estimated that ≤15% of the AS population and ≤30% of the subset with low-flow, low-gradient pattern may have CA. In patients with AS, CA is associated with increased risk of heart failure, mortality, and treatment futility with aortic valve replacement. In case of suspicion of CA, it is thus crucial to confirm the diagnosis to guide therapeutic management of AS and eventually implement recently developed pharmacological treatment dedicated to transthyretin amyloidosis. Given the high surgical risk of patients with AS and concomitant CA, transcatheter aortic valve replacement may be preferred to surgery in these patients.Entities:
Keywords: Doppler echocardiography; aortic stenosis; cardiac amyloidosis; heart failure; surgical aortic valve replacement; tafamidis; transcatheter aortic valve replacement; transthyretin
Mesh:
Year: 2019 PMID: 31753206 DOI: 10.1016/j.jacc.2019.09.056
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094